BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...
Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. The approval of gadopiclenol was based on ...
ACA Pharma: [email protected] Azurity Pharmaceuticals: [email protected] ...
Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics and safety ...
Prospective study is designed to evaluate the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI.
HOUSTON – (Nov. 17, 2022) – You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering are starting to understand exactly what goes on when doctors pump ...
Gadolinium-based contrast agents alone don't cause patients to develop nephrogenic systemic fibrosis
Even at very high doses, gadolinium-based contrast agents alone are not sufficient to cause nephrogenic systemic fibrosis (NSF) in patients with kidney problems, according to a study performed at the ...
DEAR DR. ROACH: Due to a slight genetic risk of breast cancer (my Tyrer-Cuzick Model score was 20.6%), my doctor wants me to get breast MRIs with contrast annually. I am concerned about long-term ...
Adding a contrast-enhancing agent to magnetic resonance imaging (MRI) significantly improves image quality and allows radiologists who interpret MRI scans to pick up subtle anatomic details and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback